Shire: Too Big For Its Niches
When UK specialty pharmaceutical company Shire Pharmaceuticals announced its $4 billion all-share acquisition of Canada's BioChem Pharma in December, the markets punished it with a 16% drop in share price. But Shire is getting too big to acquire merely niche product opportunities.
You may also be interested in...
The notion of building up a new drug company with the unwanted, undersized products of ever-bigger Big Pharma is hardly new. But MedPointe, with its acquisition of Carter Wallace's medical products business, is aiming to build up a new firm faster and bigger than can be done simply by in-licensing.
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.
The regulatory tools are for use in medical device development.